FDA Releases Guidance on Non-Penicillin Beta-Lactam Drugs - - BioPharm International

ADVERTISEMENT

FDA Releases Guidance on Non-Penicillin Beta-Lactam Drugs


FDA has released Guidance for Industry: Non-Penicillin Beta-Lactam Drugs:
A CGMP Framework for Preventing Cross-Contamination. In the guidance, FDA stresses the importance of implementing manufacturing controls to prevent cross-contamination of finished pharmaceuticals and APIs with non-penicillin beta-lactam drugs. FDA also provides information regarding the relative health risk of cross-reactivity in the classes of sensitizing beta-lactams (including both penicillin and non-penicillin beta-lactams). FDA states that manufacturers generally should use separate facilities for the manufacture of non-penicillin beta-lactams because those compounds pose health risks associated with cross-reactivity.

According to FDA, penicillin can be a sensitizing agent that triggers a hypersensitive exaggerated allergic immune response in some people. FDA, therefore, points out that implementing methods for preventing cross-contamination of other drugs with penicillin is a key element of manufacturing penicillin and CGMP regulations require the use of such methods.

FDA also states that non-penicillin beta-lactam drugs also may be sensitizing agents and cross-contamination with non-penicillin beta-lactam drugs can initiate the same types of drug-induced hypersensitivity reactions that penicillin can trigger, including life-threatening allergic reactions. Manufacturers of non-penicillin beta-lactam drugs, therefore, should use similar control strategies to prevent cross-contamination.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here